RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

This study tests a new nasal spray vaccine (BLB-201) to prevent RSV, a common virus that can cause serious breathing problems in young children. About 137 infants and children aged 8 to 59 months will receive either the vaccine or a placebo. The goal is to check if the vaccine is…

This study tests a single dose of an experimental RSV vaccine in Chinese adults aged 18 to 59 who have health conditions that raise their risk for severe RSV disease. Researchers will compare their immune response to that of older adults (60+) from a previous study. The trial als…

This study tests a new vaccine against respiratory syncytial virus (RSV) in adults. Phase I includes adults 18 and older to check safety of different doses. Phase II focuses on adults 60 and older to see how well the vaccine triggers an immune response and how safe it is. The vac…

This study looks at how well an RSV vaccine works and how safe it is in adults who have had a lung or kidney transplant. About 184 participants will receive the vaccine to see if their immune response lasts and if a booster dose is safe. The goal is to help protect transplant rec…

This phase 3 trial tests whether an inhaled solution of human interferon α1b can safely help children under 2 years old recover from respiratory syncytial virus (RSV) lower respiratory tract infections. The study compares the interferon treatment to a placebo, measuring improveme…

This study tests an experimental antiviral drug called S-337395 in adults with RSV who are at high risk for severe illness. Participants must have symptoms for less than 72 hours and a confirmed RSV infection. The goal is to see if the drug can lower the amount of virus in the bo…

This study tests an oral antiviral called ziresovir (AK0529) in adults at high risk for severe RSV infection, such as those with chronic lung or heart disease, weakened immune systems, or age 65 and older. Participants receive either the drug or a placebo, and researchers measure…

This early-stage trial tests a new drug called PRS CK STORM, made from a mix of immune and fat cells, to see if it can safely calm the 'cytokine storm'—a dangerous overreaction of the immune system—in people with severe lung infections from COVID-19, flu, or RSV. The study will e…

This study tests whether the antibiotic azithromycin can help children with severe RSV infection who need breathing support in the ICU. About 370 children will receive either azithromycin or a placebo for three days. The main goal is to see if the drug shortens the time they need…

This study will track 1,000 adults aged 60 and older who are hospitalized in Vietnam with breathing problems or worsening heart/lung conditions. Researchers want to find out how many of these cases are caused by RSV (respiratory syncytial virus) and which types of the virus are i…